Sartorius AG

euro adhoc: Sartorius AG
other
Group earnings (EBIT) more than doubled
Sales revenue up 5.7%
Currency-adjusted sales revenue +8.5%
Net cash flow substantially positive
Positive earnings trend expected to continue in 2005

---------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc.   The issuer is responsible for the content of this announcement. ---------------------------------------------------------------------

21.02.2005

In fiscal 2004, the Sartorius Group more than doubled its earnings before interest and taxes (EBIT) from EUR14.7 million to EUR32.5 million.  For the Biotechnology Division, EBIT was EUR17.5 million (previous year: EUR7.6 million); for the Mechatronics Division, EUR15.0 million (EUR7.1 million).  Earnings before interest, taxes, depreciation and amortization (EBITDA) reached EUR54.8 million.  This corresponds to an increase of 45.3% over the year-earlier figure of EUR37.7 million.  Earnings per share jumped from EUR0.26 to EUR0.89.

Group sales revenue rose 5.7% to EUR467.6 million from EUR442.3 million a year ago; currency-adjusted, sales revenue was up 8.5%. Sales revenue for the Biotechnology Division went up 5.4% to EUR239.4 million (EUR227.1 million).  Based on constant foreign exchange rates, the division’s sales revenue grew 8.4%.  The Mechatronics Division achieved an increase in sales revenue of 6.1% to EUR228.1 million (EUR215.1 million); currency-adjusted sales revenue for this division rose 8.5%.

The substantially positive net cash flow of EUR36.3 million (EUR33.9 million) was primarily used to reduce net debt by EUR26.1 million to EUR78.9 million.

The Executive Board will suggest to the Supervisory Board to pay significantly higher dividends in order to enable shareholders to participate in the Group’s positive business development. In 2003, dividends were EUR0.26 per preference share and EUR0.24 per ordinary share.

In fiscal 2005, the Sartorius Group is striving to continue its growth pattern and, on the basis of constant foreign exchange rates, assumes that it will achieve sales revenue growth in the mid- to upper percentage range of one digit.  In addition, the Sartorius Group is aiming at achieving an EBIT of over 8% (2004: 7.0%) of consolidated sales revenue.

The final numbers will be announced at the annual press conference and the analysts’ conference on March 21, 2005.

end of announcement                                euro adhoc 21.02.2005 10:47:21
---------------------------------------------------------------------

Further inquiry note: Andreas Wiederhold Phone +49.551.308.1668 andreas.wiederhold@sartorius.com

Branche: Biotechnology
ISIN:      DE0007165607
WKN:        716560
Index:    Prime Standard, CDAX, Prime All Share, Technologie All Share
Börsen:  Berliner Wertpapierbörse / free trade
              Hamburger Wertpapierbörse / free trade
              Baden-Württembergische Wertpapierbörse / free trade
              Börse Düsseldorf / free trade
              Bayerische Börse / free trade
              Bremer Wertpapierbörse (BWB) / free trade
              Frankfurter Wertpapierbörse / official dealing
              Niedersächsische Börse zu Hannover / official dealing



Weitere Meldungen: Sartorius AG

Das könnte Sie auch interessieren: